Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1656911

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to reduce respiratory health inequalities.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	196576
answer	answer is ministerial correction date of answer 07/09/2023 answer text <p>The NHS Long Term Plan made a commitment to tackling health inequalities and earlier intervention to detect and treat respiratory disease. NHS England has set out Core20PLUS5, a national approach to reduce healthcare inequalities at both national and system level. The approach defines a target population (the ‘Core20PLUS’) and identifies ‘5’ focus clinical areas requiring accelerated improvement.</p><p>The approach will include a focus on Chronic Obstructive Pulmonary Disease driving up uptake of COVID-19, flu and pneumonia vaccines to reduce exacerbations of the disease and to reduce emergency hospital admissions due to those exacerbations, as well as smoking cessation given the strong social gradient in smoking rates that contributes to inequalities in respiratory disease and other major causes of death.</p> answering member constituency Colchester answering member printed Will Quince question first answered 07/09/2023 15:15:02 answering member 4423 label Biography information for Will Quince
tabling member	4488 label Biography information for Martyn Day

1657370

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Allergies: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merit of each Intrgetated Care System having a (a) specialist allergy nurse and (b) specialist dietician.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	196976
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>No assessment has been made. Most services for people living with allergies are commissioned locally through integrated care boards, which are best placed to commission services according to local need.</p> answering member constituency Colchester answering member printed Will Quince question first answered 08/09/2023 13:12:19 answering member 4423 label Biography information for Will Quince
tabling member	4488 label Biography information for Martyn Day

1657371

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Allergies: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to mitigate increases in the number of hospital admissions associated with (a) allergies and (b) anaphylaxis.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	196977
answer	answer is ministerial correction date of answer 11/09/2023 answer text <p>People with allergies continue to be supported through locally commissioned NHS services. For people with rare and complex allergic conditions, specialised allergy services are commissioned by NHS England in line with the published service specification.</p><p>The National Institute of Health and Care Excellence (NICE) has produced a range of guidance to support the care of people with allergies, including recommendations on what information and support should be provided to the child or young person and their families to help manage one’s condition and avoid unnecessary hospital admissions.</p><p>On 1 October 2021, Natasha’s Law made it a legal requirement for food operators to display allergen labelling on food items pre-packed for direct sale, protecting those with allergies and giving them more confidence in the food they buy.</p><p>The Food Standards Agency (FSA) is currently considering how to improve the provision of information for people with allergies and are researching different approaches for the provision of written and verbal information to improve the accuracy and communications of allergen information. The FSA has recently commissioned several pieces of research in this area. These will provide new evidence on the nature and extent of food hypersensitivity reactions, different international approaches to written information, and the business operating models of small and micro businesses in the non-prepacked sector. These reports will be published in due course and will be presented to the FSA Board to consider next steps.</p><p>In June 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) published new guidance on the use adrenaline auto-injectors (AAIs), highlighting the latest safety advice on the steps to take during anaphylaxis. The new guidance includes a step infographic guide and video outlining the latest advice from the Commission on Human Medicines (CHM’s) working group on the safe and effective use of AAIs. It includes an easy step-by-step guide on what to do in an emergency and provides updated advice on body positioning.</p> answering member constituency Colchester answering member printed Will Quince question first answered 11/09/2023 11:20:36 answering member 4423 label Biography information for Will Quince
tabling member	4488 label Biography information for Martyn Day

1657372

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Allergies: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make it his policy to adopt Allergy UK's Patient Charter as a plan for patient rights for people living with allergic conditions.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	196978
answer	answer is ministerial correction date of answer 11/09/2023 answer text <p>The majority of allergy services are commissioned locally by integrated care boards, with a small number of specialist allergy services for patients with complex and severe allergies commissioned nationally by NHS England. The service specification specifies that centres provide equity of access to best practice standards for diagnosis and management, based on current national and international guidelines.</p><p>The Department and NHS England continue to engage with stakeholders, including Allergy UK, to understand the needs of people with allergies and how services could be improved. This includes patient and public voice membership in NHS England’s clinical reference group which provides clinical advice and leadership on specialised immunology and allergy services.</p> answering member constituency Colchester answering member printed Will Quince question first answered 11/09/2023 13:24:27 answering member 4423 label Biography information for Will Quince
tabling member	4488 label Biography information for Martyn Day

1648070

registered interest
date	27/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to support small businesses through the voluntary scheme for branded medicines pricing and access.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	191307
answer	answer is ministerial correction date of answer 03/07/2023 answer text <p>The voluntary scheme for branded medicines pricing and access (VPAS) includes strong commercial incentives in the form of freedom of list pricing and exemptions from payments for medicines containing a new active substance. Smaller companies are specifically supported through payment exemptions for those with under £5 million sales and a taper for companies between £5 million and £25 million sales.</p> answering member constituency Colchester answering member printed Will Quince question first answered 03/07/2023 12:08:34 answering member 4423 label Biography information for Will Quince
tabling member	4488 label Biography information for Martyn Day

1647553

registered interest
date	23/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Orphan Drugs: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of establishing a fund for ultra-orphan medicines.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	190966
answer	answer is ministerial correction date of answer 29/06/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) has been able to recommend medicines for very rare diseases for NHS funding through its established processes. These are now available to NHS patients in England, including gene therapies for metachromatic leukodystrophy (Libmeldy), spinal muscular atrophy (Zolgensma) and inherited retinal dystrophies (Luxturna).</p><p>In June 2022, the Government launched the Innovative Medicines Fund that will support NHS patients in England, including those with very rare diseases, to get early access to the most innovative and effective new treatments, where further data is needed to support a NICE recommendation on routine funding. The IMF is a managed access fund that provides a route for earlier patient access to the most promising new medicines while further evidence is collected to inform a long-term commissioning recommendation.</p><p>NICE’s independent committee may consider managed access if it cannot make a recommendation for routine commissioning but believes that further evidence collection during a period of managed access will sufficiently support the case for such a recommendation in the future.</p> answering member constituency Colchester answering member printed Will Quince question first answered 29/06/2023 11:04:11 answering member 4423 label Biography information for Will Quince
tabling member	4488 label Biography information for Martyn Day

1647554

registered interest
date	23/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the Voluntary Scheme for Branded Medicines Pricing and Access on access to medicines in the UK.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	190967
answer	answer is ministerial correction date of answer 29/06/2023 answer text <p>The voluntary scheme for branded medicines pricing and access (VPAS) includes strong commercial incentives to launch new products in the form of freedom of list pricing and exemptions from payments for medicines containing a new active substance. In addition, the scheme made commitments to improve the access environment for medicines which has been done through the publication of NHS England’s Commercial Framework for New Medicines, a review of the National Institute for Health and Care Excellence’s methods and processes and improved horizon scanning capabilities.</p><p>These incentives and commitments have contributed to VPAS driving significant improvements in patient access to clinically and cost-effective medicines, whilst ensuring sustainable and predictable spend growth for the National Health Service and industry during a period of economic uncertainty. This is demonstrated by data published in April 2023, by the U.S. industry body, PhRMA ranked the UK third in the G20 for availability of new medicines from 2012 to 2021.</p> answering member constituency Colchester answering member printed Will Quince question first answered 29/06/2023 10:52:50 answering member 4423 label Biography information for Will Quince
tabling member	4488 label Biography information for Martyn Day

1645309

registered interest
date	16/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Safety
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has had discussions with his counterpart in the Scottish Government on the lessons learned from the implementation of Scan4Safety in Scotland.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	189959
answer	answer is ministerial correction date of answer 26/06/2023 answer text <p>The NHS Mandate 2023 sets out the requirement for the National Health Service to adopt digital scanning. By March 2024, all trusts should adopt barcode scanning of high-risk medical devices and submission to the national, mandatory Medical Device Outcome Registry (MDOR) either directly or via a supporting electronic health record (EHR) or inventory management system that can support registry data submission. The registry will be used to improve patient safety and outcomes in procedures that use high risk medical devices.</p><p>MDOR has native barcode scanning, including Unique Device Identifier (UDI) barcodes, so will result in the whole of England having an available UDI scanning solution without having to implement a separate system. The registry was launched in May 2023 and will accept bulk uploads from existing providers’ solutions, including Scan4Safety, that meet the data quality and completeness requirements. The Outcomes and Registries programme will support provider adoption of digital solutions that enable medical device traceability on the electronic patient record.</p><p>The Secretary of State has exchanged letters with the Scottish Government setting out the UK Government’s commitment to delivering the recommendation of the Independent Medicines and Medical Devices Safety Review and on the approach for MDOR. The intention is that each Devolved Administration has the option to ‘opt in’ to existing or future technical registry developments in MDOR, building on the different data programmes and local approaches to traceability and patient outcome monitoring being taken at Devolved Administration levels.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 189960 question first answered 26/06/2023 14:33:53 answering member 4423 label Biography information for Will Quince
tabling member	4488 label Biography information for Martyn Day

1645310

registered interest
date	16/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Safety
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on the roll-out of the Scan4Safety initiative.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	189960
answer	answer is ministerial correction date of answer 26/06/2023 answer text <p>The NHS Mandate 2023 sets out the requirement for the National Health Service to adopt digital scanning. By March 2024, all trusts should adopt barcode scanning of high-risk medical devices and submission to the national, mandatory Medical Device Outcome Registry (MDOR) either directly or via a supporting electronic health record (EHR) or inventory management system that can support registry data submission. The registry will be used to improve patient safety and outcomes in procedures that use high risk medical devices.</p><p>MDOR has native barcode scanning, including Unique Device Identifier (UDI) barcodes, so will result in the whole of England having an available UDI scanning solution without having to implement a separate system. The registry was launched in May 2023 and will accept bulk uploads from existing providers’ solutions, including Scan4Safety, that meet the data quality and completeness requirements. The Outcomes and Registries programme will support provider adoption of digital solutions that enable medical device traceability on the electronic patient record.</p><p>The Secretary of State has exchanged letters with the Scottish Government setting out the UK Government’s commitment to delivering the recommendation of the Independent Medicines and Medical Devices Safety Review and on the approach for MDOR. The intention is that each Devolved Administration has the option to ‘opt in’ to existing or future technical registry developments in MDOR, building on the different data programmes and local approaches to traceability and patient outcome monitoring being taken at Devolved Administration levels.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 189959 question first answered 26/06/2023 14:33:53 answering member 4423 label Biography information for Will Quince
tabling member	4488 label Biography information for Martyn Day

1645328

registered interest
date	16/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if his Department will conduct an inquiry into potential reforms to clinical research and trials to (a) scale up, (b) speed up and (c) increase the number of such trials in (i) Scotland and (ii) the UK.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	189967
answer	answer is ministerial correction date of answer 26/06/2023 answer text <p>The Department has no plans to conduct an inquiry into clinical research reforms as work in this area is already in progress. The Government's vision for clinical research delivery, set out in ‘Saving and Improving Lives: The Future of UK Clinical Research Delivery’ (2021), aims to create a patient-centred, innovative, and digitally enabled environment. This includes improving study set-up, speed and efficiency, increasing the participation of patients within clinical trials and integrating clinical research within health and social care practice.</p><p>Lord James O’Shaughnessy was appointed by Government to conduct an independent review into the United Kingdom commercial clinical trials landscape. The Review, published 26 May, makes 27 recommendations, with an emphasis on speed of delivery, transparency of clinical research data and easier recruitment for UK clinical trials. The Government welcomes the recommendations set out in Lord O'Shaughnessy's independent review and in its response makes five headline commitments to improve the commercial clinical trials system.</p><p>No centralised information is available for clinical trials in Scotland, and the Department cannot provide a response on behalf of the Scottish Government.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/06/2023 14:29:54 answering member 4423 label Biography information for Will Quince
tabling member	4488 label Biography information for Martyn Day